ResMed
718 hedge funds and large institutions have $16.5B invested in ResMed in 2024 Q1 according to their latest regulatory filings, with 99 funds opening new positions, 293 increasing their positions, 217 reducing their positions, and 60 closing their positions.
65% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 60
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
35% more repeat investments, than reductions
Existing positions increased: 293 | Existing positions reduced: 217
16% more capital invested
Capital invested by funds: $14.3B → $16.5B (+$2.22B)
5% more funds holding
Funds holding: 687 → 718 (+31)
0.33% more ownership
Funds ownership: 56.37% → 56.7% (+0.33%)
45% less call options, than puts
Call options by funds: $213M | Put options by funds: $384M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$487M |
| 2 |
JP Morgan Chase
New York
|
+$95M |
| 3 |
Los Angeles Capital Management
Los Angeles,
California
|
+$89M |
| 4 |
Goldman Sachs
New York
|
+$43.9M |
| 5 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$284M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$168M |
| 3 |
Jane Street
New York
|
-$81.7M |
| 4 |
EPFB
Employees Provident Fund Board
Shah Alam,
Malaysia
|
-$73.8M |
| 5 |
Two Sigma Advisers
New York
|
-$69.2M |
RMD Hedge Fund Activity: Q1 2024 in Review
718 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q1 2024, worth a combined $16.5B — up 16% from $14.3B a quarter earlier.
Buyers outnumbered sellers: 99 funds opened new RMD positions and 60 closed out — a net gain of 39 holders — while 293 added to existing stakes and 217 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $487M. The largest seller was Morgan Stanley, cutting an estimated $284M.
- 718 institutional investors held ResMed (RMD) as of Q1 2024, up from 687 in Q4 2023.
- Funds reported $16.5B of ResMed stock for Q1 2024, up 16% quarter-over-quarter.
- 99 funds opened new ResMed positions in Q1 2024 and 60 closed out, a net change of +39 holders.
- The largest ResMed buyer in Q1 2024 was Bank of New York Mellon, an estimated $487M added.
- The largest ResMed seller in Q1 2024 was Morgan Stanley, an estimated $284M sold.
Based on aggregated 13F filings for Q1 2024.